Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook
View original at finance.yahoo.comIs Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Sell-side analysts have provided explicit Free Cash Flow forecasts for Novo Nordisk out to 2030, with Simply Wall St extrapolating further to 2035
60% confidenceNovo Nordisk projected Free Cash Flow reaches DKK 107.4 billion by 2030
60% confidenceNovo Nordisk scores 5 out of 6 on Simply Wall St's valuation checks
60% confidenceNovo Nordisk's 34.5% return over the last year is lagging behind its pharmaceutical peers
60% confidenceNovo Nordisk is undervalued by 65.4% based on DCF analysis, with an intrinsic value of DKK 769.11 per share
60% confidenceNovo Nordisk extrapolated Free Cash Flow reaches approximately DKK 145.9 billion by 2035
60% confidenceInvestors have been reassessing Novo Nordisk's growth expectations and risk, shifting sentiment and explaining the mix of short-term gains and long-term declines
60% confidence237 more high quality undervalued stocks are identified on Simply Wall St's platform
60% confidence
Data points we hold from this source
| Novo Nordisk · free cash flow | 52.1 billion_DKK |
| Novo Nordisk · free cash flow projected | 107.4 billion_DKK |
| Novo Nordisk · free cash flow extrapolated | 145.9 billion_DKK |
| Novo Nordisk · dcf intrinsic value | 769.11 DKK_per_share |
| Novo Nordisk · discount to intrinsic value | 65.4 percent |